343 related articles for article (PubMed ID: 33921767)
1. Syndecan-1 (CD138), Carcinomas and EMT.
Couchman JR
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921767
[TBL] [Abstract][Full Text] [Related]
2. Membrane-anchored proteoglycans of mouse macrophages: P388D1 cells express a syndecan-4-like heparan sulfate proteoglycan and a distinct chondroitin sulfate form.
Yeaman C; Rapraeger AC
J Cell Physiol; 1993 Nov; 157(2):413-25. PubMed ID: 8227171
[TBL] [Abstract][Full Text] [Related]
3. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
4. Multiple heparan sulfate chains are required for optimal syndecan-1 function.
Langford JK; Stanley MJ; Cao D; Sanderson RD
J Biol Chem; 1998 Nov; 273(45):29965-71. PubMed ID: 9792716
[TBL] [Abstract][Full Text] [Related]
5. Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors.
Bernfield M; Sanderson RD
Philos Trans R Soc Lond B Biol Sci; 1990 Mar; 327(1239):171-86. PubMed ID: 1969657
[TBL] [Abstract][Full Text] [Related]
6. Core protein structure and sequence determine the site and presence of heparan sulfate and chondroitin sulfate on syndecan-1.
Kokenyesi R; Bernfield M
J Biol Chem; 1994 Apr; 269(16):12304-9. PubMed ID: 8163535
[TBL] [Abstract][Full Text] [Related]
7. Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells.
Lim HC; Multhaupt HA; Couchman JR
Mol Cancer; 2015 Jan; 14(1):15. PubMed ID: 25623282
[TBL] [Abstract][Full Text] [Related]
8. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
Ren Z; Spaargaren M; Pals ST
Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of minican, a recombinant syndecan-1 with extensively truncated core protein.
Viklund L; Loo BM; Hermonen J; El-Darwish K; Jalkanen M; Salmivirta M
Biochem Biophys Res Commun; 2002 Jan; 290(1):146-52. PubMed ID: 11779146
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases.
Roskams T; Rosenbaum J; De Vos R; David G; Desmet V
Hepatology; 1996 Sep; 24(3):524-32. PubMed ID: 8781318
[TBL] [Abstract][Full Text] [Related]
11. The role of syndecan-1 in malignancies.
Inki P; Jalkanen M
Ann Med; 1996 Feb; 28(1):63-7. PubMed ID: 8932508
[TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate chains from glypican and syndecans bind the Hep II domain of fibronectin similarly despite minor structural differences.
Tumova S; Woods A; Couchman JR
J Biol Chem; 2000 Mar; 275(13):9410-7. PubMed ID: 10734086
[TBL] [Abstract][Full Text] [Related]
13. Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains.
Kato M; Wang H; Bernfield M; Gallagher JT; Turnbull JE
J Biol Chem; 1994 Jul; 269(29):18881-90. PubMed ID: 8034644
[TBL] [Abstract][Full Text] [Related]
14. Structural requirements of heparan sulfate for the binding to the tumor-derived adhesion factor/angiomodulin that induces cord-like structures to ECV-304 human carcinoma cells.
Kishibe J; Yamada S; Okada Y; Sato J; Ito A; Miyazaki K; Sugahara K
J Biol Chem; 2000 May; 275(20):15321-9. PubMed ID: 10809767
[TBL] [Abstract][Full Text] [Related]
15. [Proteoglycans in the liver].
Kovalszky I; Dudás J; Gallai M; Hollósi P; Tátrai P; Tátrai E; Schaff Z
Magy Onkol; 2004; 48(3):207-13. PubMed ID: 15520870
[TBL] [Abstract][Full Text] [Related]
16. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1.
Gao G; Plaas A; Thompson VP; Jin S; Zuo F; Sandy JD
J Biol Chem; 2004 Mar; 279(11):10042-51. PubMed ID: 14701864
[TBL] [Abstract][Full Text] [Related]
17. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.
Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC
Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640
[TBL] [Abstract][Full Text] [Related]
18. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M
Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857
[TBL] [Abstract][Full Text] [Related]
19. Modulated glycosylation of proteoglycans during differentiation of human B lymphocytes.
Engelmann S; Ebeling O; Schwartz-Albiez R
Biochim Biophys Acta; 1995 May; 1267(1):6-14. PubMed ID: 7779869
[TBL] [Abstract][Full Text] [Related]
20. The mutual impact of syndecan-1 and its glycosaminoglycan chains--a multivariable puzzle.
Eriksson AS; Spillmann D
J Histochem Cytochem; 2012 Dec; 60(12):936-42. PubMed ID: 22899864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
